Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND

FDA accepted RARE’s IND for UX016, a novel sialic acid prodrug targeting GNEM (GNE myopathy), and the first-in-human study is slated for H2 2026. IND acceptance clears the path to initiate clinical testing, de-risking the program and likely producing modest, company-specific upside around trial start and early data readouts.

Analysis

FDA accepted RARE’s IND for UX016, a novel sialic acid prodrug targeting GNEM (GNE myopathy), and the first-in-human study is slated for H2 2026. IND acceptance clears the path to initiate clinical testing, de-risking the program and likely producing modest, company-specific upside around trial start and early data readouts.